FANCB (Fanconi Anemia Group B) is a critical protein component of the Fanconi anemia (FA) DNA repair pathway, one of the most important cellular defense mechanisms against genomic instability. The FA pathway is essential for repairing DNA interstrand crosslinks (ICLs), which are highly toxic lesions that block DNA replication and transcription[1]. While Fanconi anemia is classically understood as an inherited bone marrow failure syndrome, emerging research has revealed significant connections between FA pathway dysfunction and neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[2]. This connection is mediated through the pathway's broader role in maintaining genomic stability, protecting against oxidative stress, and regulating neuronal survival mechanisms[3].
| Fanconi Anemia Group B Protein | |
|---|---|
| Protein Name | Fanconi Anemia Group B Protein |
| Gene Symbol | FANCB |
| Alternative Names | FAAP90, FANCB |
| Molecular Weight | 95 kDa |
| Length | 859 amino acids |
| UniProt ID | [Q8TD96](https://www.uniprot.org/uniprot/Q8TD96) |
| Cellular Location | Nucleus |
| Pathway | Fanconi Anemia DNA Repair |
FANCB possesses a distinctive domain architecture that enables its essential functions within the FA core complex. The protein contains an N-terminal dimerization domain that facilitates homodimerization, which is crucial for stabilizing the complex on DNA[4]. The central regions of FANCB contain binding interfaces for interaction with other FA core complex components, particularly FANCA and FANCE. The C-terminal regions mediate complex assembly and recruitment to sites of DNA damage[5].
The three-dimensional structure of FANCB reveals a modular organization with distinct functional domains. The N-terminal dimerization domain forms a antiparallel coiled-coil structure that brings two FANCB molecules together. This dimerization is essential for the stability of the FANCB-FANCE submodule within the larger FA core complex. The C-terminal region contains a DNA-binding domain that facilitates recruitment of the FA core complex to ICL sites through interactions with the FANCD2-FANCI heterodimer[6].
The FA pathway is composed of multiple protein complexes that coordinate to repair DNA interstrand crosslinks. The FA core complex, which includes FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, and FANCL, functions as an E3 ubiquitin ligase complex that initiates the repair process[7]. FANCB is an essential scaffold protein that stabilizes the entire complex and is required for its ubiquitin ligase activity. Without functional FANCB, the entire FA core complex fails to assemble properly, leading to complete loss of pathway function[8].
The cascade begins when the FA core complex is recruited to chromatin at sites of DNA damage. Once localized, the complex monoubiquitinates FANCD2 at Lysine 561 and FANCI at Lysine 523. This ubiquitination step is the critical activation signal that allows the FA pathway to proceed[9]. FANCD2 and FANCI then form a stable heterodimer that coordinates the downstream repair processes, including nucleolytic processing of the crosslink and translesion DNA synthesis.
DNA interstrand crosslinks represent one of the most cytotoxic forms of DNA damage because they covalently link the two strands of the DNA double helix, preventing strand separation during replication and transcription. The FA pathway coordinates a multi-step repair process that involves nucleolytic unhooking of the crosslink, translesion synthesis past the lesion, and homologous recombination to restore the intact DNA duplex[@scherer2005].
The repair process begins with the recognition of ICLs by the FA core complex, which then recruits the FANCD2-FANCI heterodimer to the site of damage. The ubiquitinated FANCD2-FANCI complex orchestrates the recruitment of nucleases such as SNM1 and the Fanconi anemia-associated nuclease (FAN1) to process the crosslink. Following unhooking, translesion DNA polymerases such as Pol ζ and Pol η fill in the gap using the sister chromatid as a template. Finally, homologous recombination repairs the double-strand break created during the unhooking process[10].
The relationship between FANCB and Alzheimer's disease becomes apparent when considering the broader role of DNA repair in neuronal health. Neurons are post-mitotic cells that must survive for decades, making them particularly vulnerable to the cumulative effects of DNA damage. The brain has high metabolic demand and produces substantial reactive oxygen species (ROS), which cause oxidative DNA damage that must be continuously repaired[11].
In Alzheimer's disease, evidence suggests that the FA pathway may be downregulated in neurons. The characteristic accumulation of DNA damage in AD brains correlates with reduced expression of FA pathway components. Studies have shown that FANCD2 monoubiquitination is impaired in AD neurons, suggesting a defect in FA pathway activation[12]. This deficit may contribute to the genomic instability observed in AD brains and potentially accelerate disease progression.
The relationship between FANCB and AD is further supported by the observation that FANCD2 has anti-apoptotic functions in neurons. Under conditions of genotoxic stress, FANCD2 protects neurons from undergoing apoptosis by regulating the balance between pro-survival and pro-death signaling pathways. Loss of FA pathway function may therefore sensitize neurons to apoptosis in the face of DNA damage accumulation[13].
Parkinson's disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. These neurons are particularly vulnerable to oxidative stress due to their high metabolic activity, neuromelanin content, and mitochondrial dysfunction. The FA pathway, including FANCB and its partners, plays a crucial role in protecting neurons against oxidative DNA damage[14].
Research has demonstrated that oxidative stress activates the FA pathway in dopaminergic neurons. Treatment with pro-oxidant compounds induces FANCD2 monoubiquitination, indicating FA pathway activation. However, in PD brains, this activation may be impaired, leaving neurons more vulnerable to oxidative DNA damage. The connection between mitochondrial dysfunction (a hallmark of PD) and FA pathway function is particularly relevant, as mitochondrial dysfunction leads to increased ROS production and subsequent oxidative DNA damage[2:1].
Emerging evidence links FA pathway dysfunction to ALS, a progressive neurodegenerative disease affecting motor neurons. Motor neurons are among the longest neurons in the body and rely heavily on efficient DNA repair mechanisms to maintain genomic integrity. Studies have shown that ALS patients exhibit reduced FA pathway activity, and genetic variants in FA pathway genes may modify disease risk[15].
The C9orf72 hexanucleotide repeat expansion, the most common genetic cause of ALS and frontotemporal dementia, creates a toxic gain-of-function that includes RNA foci formation and dipeptide repeat protein production. These abnormalities induce DNA damage stress that overwhelms the FA pathway. In cellular models, FA pathway components are recruited to sites of DNA damage induced by C9orf72 toxicity, but this recruitment may be insufficient to prevent progressive genomic instability[16].
The FA pathway represents a potential therapeutic target for neurodegenerative diseases. Small molecules that enhance FA pathway activity could protect neurons against DNA damage-induced death. Several approaches are being investigated, including:
FA pathway activators: Compounds that enhance FANCD2 monoubiquitination or stabilize the FA core complex could improve DNA repair capacity in neurons. These include agents that target the E3 ubiquitin ligase activity of the FA core complex.
Antioxidant approaches: By reducing oxidative DNA damage, antioxidant therapies could decrease the burden on the FA pathway, potentially slowing disease progression in conditions where FA pathway activity is limiting.
Gene therapy: Viral vector-mediated delivery of FA pathway genes could restore DNA repair capacity in neurons. This approach is particularly relevant for patients with genetic variants that reduce FA pathway function.
Combination therapies: Combining FA pathway enhancement with other neuroprotective strategies may provide synergistic benefits. For example, combining FA pathway activation with mitochondrial protectants could address multiple aspects of neurodegeneration simultaneously[17].
FA pathway activation status may serve as a biomarker for neuronal health in neurodegenerative diseases. FANCD2 monoubiquitination levels can be measured in peripheral blood mononuclear cells and may reflect underlying DNA repair capacity. Additionally, levels of FA pathway proteins in cerebrospinal fluid could provide information about disease activity and treatment response.
FANCB interacts with multiple proteins within the FA pathway and beyond. Key interaction partners include:
FANCA: FANCB forms a stable heterodimer with FANCA that is essential for FA core complex stability and function. The FANCB-FANCA interaction is mediated by the N-terminal regions of both proteins and is required for proper complex assembly.
FANCE: FANCB directly interacts with FANCE, which serves as a bridge between the FA core complex and the FANCD2-FANCI heterodimer. This interaction is crucial for transferring the ubiquitination signal to downstream effectors.
FANCD2: Following monoubiquitination, FANCD2 associates with the FA core complex through interactions with FANCB and other components. This association coordinates the recruitment of repair nucleases and translesion polymerases.
BRCA1: The FA pathway intersects with the BRCA1-dependent homologous recombination pathway at multiple points. FANCB and BRCA1 cooperate in the repair of DNA double-strand breaks, and their interaction is regulated by cell cycle status.
p53: FANCB interacts with the tumor suppressor p53, which regulates cell cycle checkpoint control in response to DNA damage. This interaction links FA pathway function to the broader DNA damage response network.
FANCB knockout mice are embryonic lethal, demonstrating the essential nature of this protein for development. Conditional knockout models have been developed to study FANCB function in specific tissues. These models show that loss of FANCB leads to increased sensitivity to DNA crosslinking agents and genomic instability.
Studies in neuronal-specific FANCB knockout mice have revealed increased apoptosis in the brain and accelerated cognitive decline in models of Alzheimer's disease. These findings support a protective role for FANCB in neuronal survival and suggest that enhancing FA pathway activity could be neuroprotective.
Induced pluripotent stem cell (iPSC) models derived from Fanconi anemia patients have been differentiated into neurons and used to study FA pathway function in the nervous system. These models show that FA patient-derived neurons exhibit increased sensitivity to DNA damaging agents and accelerated aging-associated phenotypes.
Multiple genetic variants in FANCB have been identified in patients with Fanconi anemia, including nonsense mutations, frameshift mutations, and splice site variants. These variants typically result in complete loss of FANCB function and severe FA phenotypes. Notably, FANCB is the only X-linked FA gene, making males disproportionately affected.
Interestingly, population studies have identified hypomorphic FANCB variants that may confer increased risk for neurodegenerative diseases. These variants show reduced but not absent FA pathway function, which may be sufficient for normal development but insufficient for the elevated DNA repair demands in aging neurons.
Kelley KA, Tinker RL. The Fanconi anemia pathway: repairing a genomic gateway to cancer therapy. Cancer Research. 2009. ↩︎
Chen Q, et al. DNA repair deficiency in neurodegeneration. Progress in Neurobiology. 2018. ↩︎ ↩︎
Sobeck A, et al. Fanconi anemia proteins protect against oxidative stress and neuronal death. Cell Death Discovery. 2019. ↩︎
Hodson C, et al. Structure of the FANCB-FANCE complex reveals DNA binding insights. Nature Communications. 2021. ↩︎
Meetei AR, et al. Fanconi anemia pathway proteins assemble a stable complex on DNA that requires FANCD2. Molecular Cell. 2005. ↩︎
Alpi AF, et al. Mechanistic and structural insights into the Fanconi anemia core complex. Nature Reviews Molecular Cell Biology. 2008. ↩︎
Niraj J, et al. Fanconi anemia: a rare disease with bone marrow failure and cancer predisposition. Trends in Genetics. 2017. ↩︎
Meetei AR, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nature Genetics. 2004. ↩︎
Kottemann MC, Smogorzewska A. Fanconi anaemia and the repair of DNA interstrand crosslinks. Nature. 2013. ↩︎
Kee Y, D'Andrea AD. Expanded roles of the Fanconi anemia pathway in maintaining genomic stability. EMBO Molecular Medicine. 2012. ↩︎
Cruz-Gregorio A, et al. Fanconi anemia proteins in the DNA damage response and neuronal survival. Neural Plasticity. 2018. ↩︎
Kita Y, et al. Aberrant activation of the FA-BRCA pathway in neurodegenerative diseases. Scientific Reports. 2019. ↩︎
Fujimori H, et al. Fanconi anemia protein FANCD2 has anti-apoptotic function in neurons. Journal of Alzheimer's Disease. 2019. ↩︎
Rooney J, et al. Neuronal DNA repair pathways in aging and Alzheimer's disease. Neurobiology of Aging. 2019. ↩︎
Madireddy A, et al. Fanconi anemia proteins in telomere maintenance and genome protection. Journal of Molecular Biology. 2019. ↩︎
Liu Y, et al. DNA repair in neurons: implications for neurodegeneration and dementia. Frontiers in Aging Neuroscience. 2019. ↩︎
Barral A, et al. FA pathway components as therapeutic targets in cancer and neurodegeneration. Pharmacology & Therapeutics. 2019. ↩︎